Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

Launched by GLAXOSMITHKLINE · Oct 28, 2010

Keywords

ClinConnect Summary

Androgenetic alopecia is a common, androgen-induced, pattern of progressive loss of scalp hair with an onset at any age after puberty in genetically predisposed people. The influence of androgens on scalp hair growth is mediated by local and systemic conversion of testosterone to dihydrotestosterone , by the enzyme 5 alpha-reductase. 5 alpha-reductase has been shown to exist as 2 isoenzyme forms, Type 1 and Type 2. Type 1 is predominantly located in the skin, both in the hair follicles and sebaceous glands, and is also found in the liver and kidney . Type 2 is the dominant form in male geni...

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Norwood-Hamilton Type III vertex, IV, or V
• Exclusion Criteria:
• • History or evidence of hair loss other than androgenetic alopecia
• • Scarring of the scalp
• • Use of dutasteride in previous 18 months
• • Use of finasteride within previous 12 months
• • Hair transplantation or hair weaving within 6 months
• • Use of Minoxidil within previous 6 months
• • Use of drugs with anti-androgenetic/androgenetic properties within previous 6 months
• • Use of Drugs that cause hypertrichosis or hypotrichosis within previous 6 months
• • Light or laser treatment of scalp within previous 3 months
• • Cosmetic products aimed at improving or correcting signs of hair loss within previous 2 weeks